Plasma hydroxyproline fractions in patients with dialysis osteodystrophy

Area of Science:

• Biochemistry
• Nephrology
• Bone Metabolism

Background:

• Maintenance hemodialysis therapy (MHT) is associated with renal osteodystrophy.
• Plasma hydroxyproline is a marker of bone turnover.
• Understanding hydroxyproline metabolism is crucial for managing bone disease in MHT patients.

Purpose of the Study:

• To investigate plasma hydroxyproline fractions in patients with MHT and varying degrees of dialysis osteodystrophy.
• To assess the relationship between hydroxyproline fractions and histological bone findings.
• To evaluate hydroxyproline catabolism in MHT patients.

Main Methods:

• Measurement of plasma hydroxyproline fractions (total, peptide-bound, free) in 17 normal subjects and 54 MHT patients.
• Classification of MHT patients into groups based on radiological and histological findings (radiologically normal, histologically normal, osteitis fibrosa).
• Statistical analysis to compare hydroxyproline levels and ratios between groups.

Main Results:

• Mean total plasma hydroxyproline concentrations were significantly elevated in all MHT patient groups.
• Increases were primarily due to peptide-bound and free hydroxyproline fractions, with highest values in osteitis fibrosa.
• The free to peptide-bound hydroxyproline ratio was significantly lower in patients with osteitis fibrosa.

Conclusions:

• Hydroxyproline catabolism is not inhibited in patients undergoing haemodialysis.
• Elevated peptide-bound and free hydroxyproline fractions are indicative of bone disease in MHT patients.
• Measurements of both free and peptide-bound hydroxyproline are sensitive markers for identifying osteitis fibrosa.